Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
ViiV Healthcare gains CHMP positive opinion for Juluca (dolutegravir/rilpivirine) in Europe
ViiV Healthcare announced that the European Committee for Medicinal Products for Human Use issued a Positive Opinion for Juluca.
-
Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over
GSK announced the EC has approved Shingrix for the prevention of shingles & PHN in adults aged 50 years or older.
-
GSK update regarding Pfizer Inc. Consumer Healthcare
GlaxoSmithKline plc (LSE/NYSE: GSK) today confirms it has withdrawn from the process relating to Pfizer’s Consumer Healthcare business.
-
GSK starts phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
GSK today announced the start of a phase III study investigating Benlysta (belimumab)
-
GSK announces positive EU approval for labelling update to Relvar Ellipta in patients with asthma
GSK & INVA announced that the EC has approved a label update for the use of once daily Relvar Ellipta (fluticasone furoate/vilanterol,FF/VI)
-
New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age
New data published in The Lancet from a Phase III clinical trial with Fluarix Tetra which prevented influenza in children 6 to 35 months
-
ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis
INSPIRING study results contribute to extensive body of evidence for dolutegravir
-
Nucala (mepolizumab) improved asthma control in patients uncontrolled on Xolair (omalizumab)
Positive clinical study outcomes observed for severe eosinophilic asthma patients uncontrolled on omalizumab
-
GSK receives European approval for expanded indication for Fluarix Tetra (Influenza Vaccine) for ages six months and older
GSK announced the expanded indication for Fluarix Tetra has been approved in Europe.
-
GSK submits landmark IMPACT data to European Medicines Agency to support expanded label for Trelegy Ellipta
GlaxoSmithKline plc and Innoviva, Inc. announce submission of landmark IMPACT data to the European Medicines Agency
-
ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment
TANGO will seek to enrol approximately 550 adults with HIV-1, from clinical trial sites in North America, Europe, Australia, and Japan.
-
ViiV Healthcare files patent infringement litigation against Gilead Sciences Inc. over bictegravir
ViiV Healthcare announces it has filed patent infringement litigation against Gilead Sciences Inc.
-
GSK delivers improvements in sales, margins and cash flow in 2017
Total EPS 31.4p, +67% AER, +36% CER; Adjusted EPS 111.8p, +11% AER, +4% CER
-
GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age
GlaxoSmithKline plc announced that it has received Breakthrough Therapy Designation from the U.S. FDA for its meningitis B vaccine Bexsero
-
GSK’s Shingrix receives positive opinion from the CHMP in Europe for the prevention of shingles in adults aged 50 and over
Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses, with a two-to-six month interval between doses.
-
GSK announces CHMP positive opinion for labelling update to Relvar Ellipta in patients with asthma
A positive CHMP opinion is one of the final steps before marketing authorisation is updated by the European Commission.
-
GSK responds to the AMR Benchmark
New AMR Benchmark provides useful analysis of industry’s contribution to addressing the public health threat of antimicrobial resistance.
-
FDA approves US label update on ICS/LABA combinations in asthma, based on review of safety data
Boxed warning removed from ICS/LABA combination products, including BREO ELLIPTA, ADVAIR DISKUS and ADVAIR HFA.
-
GSK submits regulatory application for single-dose tafenoquine for the treatment of Plasmodium vivax malaria to Australia’s Therapeutic Goods Administration
Innovative science drives progress in developing medicines for infectious diseases.
-
GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US
First targeted treatment approved for this rare eosinophil-driven disease
